A5064026892- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Hormonal and reproductive studies
- Renal cell carcinoma treatment
- Multiple Myeloma Research and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Healthcare Systems and Public Health
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- COVID-19 Impact on Reproduction
- COVID-19 Clinical Research Studies
- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Renal and related cancers
- SARS-CoV-2 and COVID-19 Research
- Cancer, Hypoxia, and Metabolism
University of Florence
2024-2025
Institute of Oncology Research
2024
Ente Ospedaliero Cantonale
2024
Azienda Ospedaliero-Universitaria Careggi
2024
Università della Svizzera italiana
2023
507 Background: Patients with oligometastatic (OM-) or oligoprogressive renal cell carcinoma (OP-RCC) may benefit from metastasis-directed therapy (MDT) alone in combination systemic therapies. Literature data are available for IMDC favorable-risk patients low-volume and asynchronous metastases, particularly to the lung. However, OM- OP-RCC represent a heterogeneous population, current knowledge on use of MDTs extra-lung metastases remains limited. Methods: This was real-world, multicenter,...
Abstract Background Metastatic castration-resistant prostate cancer remains a challenging condition to treat. Among the available therapeutic options, androgen receptor signaling inhibitors abiraterone acetate plus prednisone (AA) and enzalutamide (Enza), are currently most used first-line therapies in clinical practice. However, validated indicators of prognosis this setting still lacking. In study, we aimed evaluate prognostic model based on time metastatic disease presentation (after...
Background: Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most administered first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). AA Enza have shown similar overall survival (OS) benefits there is no consensus upon best option mCRPC treatment. Volume of disease may represent a useful biomarker to predict response therapy in such patients. Objectives: In this study, we seek...
e16503 Background: In regard to resectable muscle-invasive bladder cancer (MIBC) patients, treatment with radical cystectomy (RC) and perioperative platinum-based chemotherapy (CT) (neoadjuvant or adjuvant) represents the standard of care. Perioperative can improve overall survival (OS), most robust evidence are in favor neoadjuvant CT. RealBLADDER is an observational study aiming describe use impact on CT for patients MIBC Italian real-world setting. Methods: a multicentric, observational,...
107 Background: The optimal management of mCRPC in men aged ≥75 is challenging, and there a paucity clinical data the literature. Although AA E are commonly used as 1 st line Rx for mCRPC, it unclear whether use upfront D mCSPC may impact their efficacy or safety this elderly population. Methods: Patients who started within January 2015 - April 2019 were identified from IRB approved databases 10 institutions Europe, South North America. Demographic clinicopathological collected available...
<sec> <title>BACKGROUND</title> Real-time remote monitoring and timely detection of clinical deterioration, especially for high-risk haematological oncological outpatients, continues to be a challenge. Our pilot study, one the few within this specific context, investigated between October 2021 July 2022 telemedicine- wearable-based system detect early changes in vital signs among outpatients. </sec> <title>OBJECTIVE</title> primary objective was assess patients' perceived sense safety at...